Table 2.
Prognostic factors for overall survival
| Univariable analysis |
Multivariable analysis |
|||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age, continuous (years) | 0.99 | 0.98-1.00 | 0.003 | 1.00 | 0.98-1.01 | 0.700 |
| ECOG PS, 0-1 vs. 2-4 | 9.06 | 5.33-15.41 | <0.001 | 4.10 | 2.09-8.03 | <0.001 |
| Gender, female vs. male | 1.06 | 0.76-1.46 | 0.739 | |||
| Etiology, viral vs. non-viral | 0.59 | 0.46-0.75 | <0.001 | 0.81 | 0.61-1.07 | 0.135 |
| mALBI, grade 1 vs. grade 2a | 1.94 | 1.49-2.53 | <0.001 | 1.49 | 1.12-1.98 | 0.006 |
| mALBI, grade 1 vs. grade 2b-3 | 4.95 | 3.82-6.41 | <0.001 | 2.41 | 1.70-3.45 | <0.001 |
| AFP, continuous | 1.00 | 1.00-1.00 | <0.001 | 1.00 | 1.00-1.00 | 0.001 |
| PIVKA-II, continuous | 1.00 | 1.00-1.00 | 0.708 | |||
| Child-Pugh class, A vs. B | 2.85 | 2.17-3.74 | <0.001 | 0.92 | 0.63-1.34 | 0.665 |
| Child-Pugh class, A vs. C | 31.47 | 16.34-60.6 | <0.001 | 4.57 | 2.03-10.30 | <0.001 |
| Presentation, solitary vs. multiple | 2.62 | 2.07-3.32 | <0.001 | 1.40 | 0.93-2.10 | 0.103 |
| Presentation, solitary vs. diffuse | 4.19 | 2.86-6.14 | <0.001 | 1.12 | 0.70-1.78 | 0.640 |
| Size, 5-10 vs. >10 (cm) | 1.84 | 1.46-2.32 | <0.001 | 1.04 | 1.01-1.08 | 0.043 |
| Vascular invasion, negative vs. positive | 1.35 | 1.01-1.81 | 0.04 | 0.82 | 0.62-1.05 | 0.061 |
| Biliary tract invasion, negative vs. positive | 1.24 | 0.78-1.97 | 0.365 | |||
| PVTT classification, Vp0 vs. Vp1/2 | 1.33 | 0.96-1.85 | 0.083 | 0.80 | 0.53-1.20 | 0.274 |
| PVTT classification, Vp0 vs. Vp3/4 | 3.09 | 2.44-3.91 | <0.001 | 1.43 | 1.02-2.00 | 0.036 |
| LN metastasis, negative vs. positive | 2.10 | 1.62-2.72 | <0.001 | 1.34 | 0.99-1.81 | 0.062 |
| mUICC stage, stage II vs. III | 2.24 | 1.56-3.22 | <0.001 | 0.74 | 0.44-1.29 | 0.284 |
| mUICC stage, stage II vs. IVA | 4.55 | 3.19-6.49 | <0.001 | 0.82 | 0.37-1.81 | 0.624 |
| mUICC stage, stage II vs. IVB | 5.10 | 3.54-7.37 | <0.001 | 0.72 | 0.35-1.49 | 0.378 |
| BCLC stage, A-B vs. C-D | 3.67 | 2.78-4.84 | <0.001 | 1.65 | 1.03-2.82 | 0.032 |
| Treatment, sorafenib vs. BSC | 3.53 | 2.40-5.19 | <0.001 | 1.86 | 1.13-3.13 | 0.018 |
| Treatment, sorafenib vs. surgery | 0.09 | 0.06-0.14 | <0.001 | 0.17 | 0.10-0.28 | <0.001 |
| Treatment, sorafenib vs. other local treatments | 0.45 | 0.34-0.60 | <0.001 | 0.55 | 0.40-0.76 | <0.001 |
The foreparts of the comma were set as the reference groups in the multivariable analysis.
HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; mALBI, modified albumin-bilirubin score; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence-II; PVTT, portal vein tumor thrombosis; LN, lymph node; mUICC, modified International Union Against Cancer; BCLC, Barcelona Clinic Liver Cancer; BSC, best supportive care.